Having trouble accessing articles? Reset your cache.

ASH abstract shows U.S. study confirms efficacy for Legend’s BCMA CAR T

New data from a U.S. trial of anti-BCMA CAR T therapy JNJ-4528 (LCAR-B38M) from J&J and partner Legend Biotech may calm any lingering concerns that data from a previous trial had been manipulated. The data, along with updated results from bluebird’s next generation BCMA-targeted CAR therapy, are slated for presentation at this year’s American

Read the full 548 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE